Clinical Trial 17933

Cancer Type: Gynecological Tumor
Interventions:Caelyx; Doxil (doxorubicin liposome); Yondelis (Trabectedin)

Study Type: Treatment
Phase of Study: Phase III


    Study Title

    A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer


    The main purpose of this study is to see if patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer who were previously treated for the disease live longer if they are treated with a combination of trabectedin and DOXIL as compared to DOXIL alone. The study will also measure the safety of the trabectedin and DOXIL combination, and how well it is tolerated.


    Primary objective- to compare the OS after treatment with trabectedin + DOXIL combination therapy to that observed after treatment with DOXIL monotherapy for subjects with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who have received 2 previous lines of platinum-based chemotherpy. Secondary objectives- to evaluate PFS, to evaluate the objective response rate (ORR), to characterize the plasma PK of trabectedin using a sparse sampling scheme in the trabectedin+DOXIL treatment group, to evaluate the safety of trabectedin+DOXIL combination therapy and DOXIL monotherapy. Exploratory objectives- to conduct pharmacogenomic evaluations of OS, PFS, and other endpoints in subjects with and without mutations in BRCA1 or BRCA2 and then evaluate patient-reported outcomes (PROs).

    Inclusion Criteria


  • Histologically proven advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer
  • Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
  • Received first-line treatment with a platinum-based regimen and had no evidence of disease progression for >/= 6 months after the last dose
  • Received second-line treatment with a platinum-based regimen, with progression of disease after attaining a complete response (CR) or partial response (PR)
  • Progression of disease based on imaging after the second-line platinum-based regimen (individuals treated with a pegylated liposomal doxorubicin-containing regimen as a second-line therapy are eligible if subsequent disease progression occurs >/=9 months from the first dose)
  • Evidence of measurable disease at screening as evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) (Version 1.1)
  • Able to receive intravenous (IV) dexamethasone or an equivalent IV corticosteroid
  • Have a known BRCA 1/2 mutation status (for participants who do not have a known BRCA 1/2 status at screening, a blood sample will be collected to determine the status with the results available prior to randomization
  • Laboratory values within protocol -defined parameters
  • Have left ventricular ejection fraction by multigated acquisition scan (MUGA) scan or 2D-ECHO within normal limits for the institution
  • Have side effects (except alopecia) of prior treatment resolved to at least Grade 1 according to the National Cancer Institute - Common Terminology Criteria of Adverse Events (NCICTCAE) (Version 4.0)
  • Have a negative urine or serum pregnancy test at screening
  • Agrees to protocol-defined use of effective contraception

  • Exclusion Criteria


  • Diagnosis of ovarian carcinoma with mucinous histology
  • Had more than 2 prior lines of chemotherapy
  • Prior exposure to trabectedin or hypersensitivity to any of the excipients
  • Prior treatment with doxorubicin or other anthracycline at cumulative doses greater than 300 mg/m^2 (calculated using doxorubicin equivalent doses: 1 mg doxorubicin = 1 mg Doxil/Caelyx = 1.8 mg epirubicin = 0.3 mg mitoxantrone = 0.25 mg idarubicin)
  • Unwilling or unable to have a central venous catheter placed
  • Pregnant or breast-feeding
  • Less than 3 weeks from radiation therapy, experimental therapy, hormonal therapy, prior chemotherapy, or biological therapy
  • History of another neoplastic disease (except non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin or cervical carcinoma in situ adequately treated) unless in remission for 5 years
  • Known allergies, hypersensitivity, or intolerance to Doxil, dexamethasone, or their excipients
  • Known history of central nervous system metastasis
  • Known significant chronic liver disease, such as cirrhosis or active hepatitis (potential participants who test positive for hepatitis B surface antigen or hepatitis C antibodies are allowed provided they do not have active disease requiring antiviral therapy)
  • Had a myocardial infarct within 6 months before enrollment, New York Heart Association (NYHA) Class II or greater heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic or active conduction system abnormalities
  • Has any of the following medical conditions: uncontrolled diabetes, psychiatric disorder (including dementia) that prevents compliance with protocol, uncontrolled seizures, newly diagnosed deep vein thrombosis, active systemic infection that is likely to interfere with study procedure or results
  • Has any condition that, in the opinion of the investigator, would compromise the well-being of the participant or the study or prevent the participant from meeting or performing study requirements